» Articles » PMID: 38649531

Comparison of Clinicopathological and Prognostic Features of Breast Cancer Patients Younger Than 40 Years and Older Than 65 Years

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2024 Apr 22
PMID 38649531
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study aims to compare the clinicopathological and prognostic features of women aged 40 years and younger and 65 years and older with breast cancer.

Methods: Between January 2011 and December 2021, 136 female cases aged 40 years and younger and 223 female cases aged 65 and over were identified among all cases (1395 cases) registered as breast cancer in the file archives of Afyonkarahisar Health Sciences University Faculty of Medicine, Department of Medical Oncology for the study. A Chi-square (× 2) test was used for categorical variables, and an independent sample t-test for continuous variables. Log-rank test and Kaplan-Meier plots were used for survival analysis. For the statistical evaluation, p < 0.05 was considered significant.

Results: Both overall survival (p < 0.01) and breast cancer-specific survival (BCSS) (p = 0.01) were significantly worse in the older group. BCSS were significantly worse in the older group in Luminal B (HER2-) (p = 0.013) and HR- HER2+ (p = 0.015) subtypes detected. In multivariate Cox regression analysis, only the presence of metastases at diagnosis or follow-up (p < 0.001) and ECOG PS 2-3 status (p = 0.001) were associated with an increased risk of breast cancer-specific death.

Conclusion: To our knowledge, no study directly compares these two groups. In our study, similar to many studies, more aggressive tumor features were found in young patients, but unlike many studies, mortality was found to be significantly higher in older patients. The presence of metastasis and poor ECOG PS were found to be the most influential factors in breast cancer-specific death risk.

Citing Articles

Comparison of clinical characteristics and pathologic complete response rate after neoadjuvant chemotherapy in women under 35 years and older women with breast cancer.

Dou H, Gao T, Li Z, Jia S, Luo D, Ba Y Gland Surg. 2024; 13(11):1907-1920.

PMID: 39678411 PMC: 11635561. DOI: 10.21037/gs-24-293.

References
1.
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

2.
Mathew J, Lee S, Syed B, Morgan D, Ellis I, Cheung K . A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts. Breast Cancer Res Treat. 2014; 147(3):671-4. DOI: 10.1007/s10549-014-3094-4. View

3.
Bouferraa Y, Haibe Y, Chedid A, Jabra E, Charafeddine M, Temraz S . The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study. BMC Cancer. 2022; 22(1):27. PMC: 8722326. DOI: 10.1186/s12885-021-09100-z. View

4.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

5.
Cazap E . Breast Cancer in Latin America: A Map of the Disease in the Region. Am Soc Clin Oncol Educ Book. 2018; 38:451-456. DOI: 10.1200/EDBK_201315. View